health · humanitarian · family: it worked in the lab
one in tenpills is a lie
No affordable field test distinguishes substandard medicines at point of dispensing
Problem statement
WHO estimates at least 1 in 10 medical products in low- and middle-income countries is substandard or falsified. UNODC reports that as many as 267,000 deaths per year in sub-Saharan Africa are linked to falsified and substandard antimalarial medicines, and up to 169,271 more to falsified and substandard antibiotics used to treat severe pneumonia in children; sub-therapeutic antibiotics also drive antimicrobial resistance. Quality verification requires HPLC or mass spectrometry in centralized laboratories, but substandard products enter fragmented distribution networks and reach patients at peripheral health facilities and open-air markets where no testing infrastructure exists. No affordable, reliable field test can verify both drug identity and approximate dosage at the point where patients actually receive medicines.
Why this matters
Beyond direct mortality, substandard medicines undermine trust in health systems and accelerate AMR by exposing pathogens to sub-therapeutic drug concentrations. WHO's Global Surveillance and Monitoring System received 1,500 reports of substandard or falsified products in its first four years of operation (2013 to mid-2017), a figure WHO itself treats as a fraction of the true problem. Countries spend an estimated US$30.5 billion per year on substandard and falsified medical products (WHO); in sub-Saharan Africa, caring for people who have used falsified or substandard antimalarials alone costs an estimated $12 million to $44.7 million every year (WHO, cited in UNODC 2023).
What’s been tried and why it hasn’t worked
Inspecting packaging by eye is not enough: the increasing sophistication of falsified medicines calls for techniques that detect anomalies "not apparent to the naked eye" (Vickers et al. 2018). The Notre Dame Paper Analytical Device (PAD) uses colorimetric chemistry for screening at $2 per card but is designed for qualitative screening of active ingredients, not for measuring dosage, and its sensitivity drops for formulations with a low proportion of active ingredient (Vickers et al. 2018). A 2018 systematic review catalogued 41 field-screening devices — from handheld Raman and NIR spectrometers (e.g., TruScan RM) to the TLC-based GPHF Minilab — at prices from under US$10 to over US$20,000; only six had been field-tested, and the nine spectroscopic devices tested for quantifying API content "required highly trained operators using complex API-specific calibration models, and are therefore not field-ready" (Vickers et al. 2018). Scratch-code track-and-trace systems (mPedigree's Goldkeys) let buyers verify packaging authenticity by SMS but cannot verify actual drug content. None yet combines low device and per-test cost, semi-quantitative dosage verification, usability by non-specialist health workers, and coverage of the most commonly falsified essential medicines — the review concludes it is "unlikely, with current technology, that one device will be able to effectively monitor the quality of all medicines."
What would unlock progress
An inexpensive handheld device that verifies both identity and approximate concentration of active pharmaceutical ingredients across the most commonly falsified essential medicines. This likely requires advances in miniaturized spectroscopy (SERS, portable Raman, or paper-based ELISA) combined with ML spectral libraries trained on local formulations. Alternatively, paper-based lateral flow assays that go beyond binary pass/fail to provide semi-quantitative dosage estimation for key drug classes.
Entry points for student teams
A team could build and test a low-cost SERS substrate optimized for detecting one commonly falsified drug class (e.g., artemisinin-based antimalarials) at semi-quantitative concentrations. Alternatively, a team could benchmark existing portable spectroscopy tools against reference HPLC results for a panel of medicines common in LMICs, quantifying the accuracy-cost frontier. Analytical chemistry, spectroscopy, and global health skills apply.
Genes
Structural cousins: stuck the same way, in other fields
Sources
WHO news release (28 Nov 2017), "1 in 10 medical products in developing countries is substandard or falsified," WHO fact sheet, "Substandard and falsified medical products" (3 December 2024), UNODC (1 Feb 2023), *Trafficking in Medical Products in the Sahel* (press release "Fake medicines kill almost 500,000 sub-Saharan Africans a year: United Nations Office on Drugs and Crime (UNODC) report," ); Vickers S., Bernier M., Zambrzycki S., Fernandez F.M., Newton P.N., Caillet C. (2018), "Field detection devices for screening the quality of medicines: a systematic review," BMJ Global Health 3:e000725, doi:10.1136/bmjgh-2018-000725, University of Notre Dame Paper Analytical Device Project, Accessed 2026-08-21. go to source 1 ↗ go to source 2 ↗ go to source 3 ↗ go to source 4 ↗ go to source 5 ↗
Working notes
Notes made while writing and checking this brief, shown as written. They use working shorthand.
The problem is `wrong-stakeholder` because quality verification currently targets the supply chain (manufacturers, regulators, importers) but misses the last mile where patients receive medicines. The binding constraint is technical — no analytical chemistry approach achieves the required performance/cost/usability combination for point-of-dispensing use. Distinct from existing AMR briefs (`health-amr-diagnostic-stewardship-integration-gap`, `health-amr-antibacterial-pipeline-collapse`) which address resistance diagnostics and drug development, not medicine quality verification.
Reconciliation 2026-08-21: The surveillance figure was wrong by two orders of magnitude: "~150,000 reports since 2013" does not exist anywhere — WHO's own 2017 release says "WHO has received 1500 reports of cases of substandard or falsified products" in the GSMS's first four years (2013 to 30 June 2017); corrected. The "$12 billion/year" sub-Saharan economic burden could not be sourced and appears to be a conflation of two real WHO figures — the global "US$ 30.5 billion per year" LMIC spend on substandard/falsified products (WHO fact sheet, 3 Dec 2024) and the "$12 million to $44.7 million every year" cost of caring for people who used falsified/substandard malaria products in sub-Saharan Africa (WHO estimate cited in UNODC's 2023 Trafficking in Medical Products in the Sahel press release); replaced with both verified figures. The 267,000 antimalarial figure is real (UNODC 2023) but was overstated as "falsified antimalarials alone kill" — UNODC's wording is "as many as 267,000 deaths per year are linked to falsified and substandard antimalarial medicines"; rephrased and the companion figure (up to 169,271 deaths linked to falsified/substandard antibiotics for childhood pneumonia) added. PAD cost corrected $1 → $2 per card (padproject.nd.edu purchase page). The "$15,000–$45,000" device price range could not be sourced, and the GPHF Minilab was misclassified as Raman/NIR spectroscopy (it is a TLC-based kit at roughly €3 in materials per test); both replaced with the verified range and framing from Vickers et al. 2018, BMJ Global Health 3:e000725 (41 devices, "<US$10 to >US$20 000", six field-tested, quantitative methods "not field-ready"). mPedigree's system is cloud-based SMS scratch-code verification (Goldkeys), not blockchain; descriptor corrected. The "<$500 device / <$5 per test / 50 most commonly falsified medicines" specification had no source and was reworded without invented numbers, as was the "$500" target in What Would Unlock Progress. The 1-in-10 WHO estimate verified clean ("At least 1 in 10 medicines in low- and middle-income countries are substandard or falsified," WHO fact sheet). The vague Source line ("PMC Substandard and falsified medicines in Africa") was rebuilt with full citations for the sources actually used. All URLs on the Source line fetched live 2026-08-21.
Reconciliation 2026-09-29: Fact repair after a site review read this write-up against all five sources on its Source line. Each was fetched in full on 2026-09-29 from the address given there: the WHO news release of 28 November 2017, the WHO fact sheet of 3 December 2024, the UNODC press release of 1 February 2023, Vickers et al. 2018 (https://pmc.ncbi.nlm.nih.gov/articles/PMC6135480/), and the Notre Dame purchase page. (1) The text said approaches that quantify API content "required highly trained operators using complex API-specific calibration models, and are therefore not field-ready." In the review that sentence is about the nine spectroscopic devices that were tested for quantitation. It is not about every method that measures content; the review lists the Minilab, paper cards and dipsticks as a separate group. The sentence now names the nine spectroscopic devices. (2) The text said the Paper Analytical Device "only provides pass/fail screening for a limited set of active ingredients" and "cannot detect incorrect dosage or degraded formulations." The purchase page says nothing about limits. The review says the device is designed for qualitative screening of active ingredients and some excipients, that expert readers can tell different strengths apart, and that its sensitivity is reduced for formulations with a low proportion of active ingredient. It does not say the device cannot detect degraded products. The sentence now follows the review. (3) "Packaging analysis (holograms, barcodes) is easily counterfeited" is in none of the five sources. It was replaced with what the review says: the increasing sophistication of falsified medicines requires techniques that detect anomalies of packaging or product "not apparent to the naked eye." Confirmed against the sources and left as written: the Source line's titles, dates, authors, journal and DOI; the 1 in 10 estimate; 267,000 and 169,271 deaths, both worded as "linked to"; 1,500 reports in the first four years to 30 June 2017, which WHO calls likely a small fraction of the problem; US$30.5 billion per year; $12 million to $44.7 million per year; $2 per card; 41 devices; prices from under US$10 to over US$20,000; six devices field-tested, among them the TruScan RM and the GPHF-Minilab; the Minilab as a thin-layer chromatography kit; and the closing quotation about one device. NOT checked: the sentence on mPedigree's Goldkeys. None of the five sources mentions it. The company's home page (https://mpedigree.com/, fetched 2026-09-29) confirms that Goldkeys is its platform against counterfeiting, but the page does not describe checking by SMS, so that sentence is left as written. The statements that no affordable field test exists, in the title and the Problem Statement, are this write-up's own summary; the review's own conclusion is narrower, that most devices lack independent evaluation in field settings. Genes untouched.